SAM
ENGN icon

Sectoral Asset Management’s enGene Therapeutics ENGN Stock Holding History

Sectoral Asset Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,700
Closed -$52.4K – 101
2025
Q1 		$52.4K Sell
11,700
-67,219
-85% -$417K 0.04% 84
2024
Q4 		$525K Sell
78,919
-15,300
-16% -$119K 0.35% 56
2024
Q3 		$622K Buy
+94,219
New +$701K 0.37% 61

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Sectoral Asset Management's ENGN Position: Q2 2025 in Review

Sectoral Asset Management sold out of enGene Therapeutics (ENGN) in Q2 2025, closing a stake of 11,700 shares — an estimated $52.4K sold.

Sectoral Asset Management first reported a position in ENGN in Q3 2024 and held it in 3 quarters. The position peaked at $622K in Q3 2024. 36 funds tracked by Wall St. Rank hold ENGN as of Q2 2025.

  • Sectoral Asset Management reported no remaining enGene Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sectoral Asset Management sold 11,700 enGene Therapeutics shares in Q2 2025, an estimated $52.4K.
  • Sectoral Asset Management first reported a position in enGene Therapeutics in Q3 2024 and held it in 3 quarters.
  • Sectoral Asset Management's enGene Therapeutics position peaked at $622K in Q3 2024.
  • 36 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2025.

Based on Sectoral Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.